Observational studyGut2018
Cancer risk and survival in
Erratum issuedOpen access · greenAbstract readMulticenter StudyObservational Study
In one paragraph
Observational study in Gut, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 329 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
329citing papers in PubMed, 5 pooled it
34.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
329 citing papers in PubMed, 5 syntheses or guidelines pooled it, 551 citations in OpenAlex.
- Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer.International journal of clinical oncology · 2026Guideline
- [Gender-specific differences in the development of colorectal cancer in Lynch syndrome patients-A systematic review].Chirurgie (Heidelberg, Germany) · 2024Pooled it
- Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023Guideline
- The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.International journal of cancer · 2022Pooled it
- Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.BJOG : an international journal of obstetrics and gynaecology · 2022Guideline
- Improving Lynch syndrome detection: a mixed-methods process evaluation of a hybrid type III effectiveness-implementation trial.BMC health services research · 2024Trial
- Cancer Prevention with Resistant Starch in Lynch Syndrome Patients in the CAPP2-Randomized Placebo Controlled Trial: Planned 10-Year Follow-up.Cancer prevention research (Philadelphia, Pa.) · 2022Trial
- Trial
- Outcomes of germ line testing for children with hematologic malignancies undergoing hematopoietic cell transplantation.Blood advances · 2026Article
- Exercise-associated epigenetic remodeling and TCR repertoire dynamics in Lynch syndrome carriers.iScience · 2026Article
- Hereditary diffuse gastric cancer in progress: Comparative lessons from Lynch syndrome.European journal of human genetics : EJHG · 2026Review
- Clinical Benefit of Pembrolizumab in Lynch Syndrome-Associated Advanced Ovarian Cancer With GermlineClinical case reports · 2026Article
- Characterization of putative germline pathogenic variants in 27 candidate cancer-predisposing genes in 813 cats using a feline-specific multiplex targeted sequencing.Scientific reports · 2026Article
- Progress, challenges, and future directions of pancreatic cancer surveillance in high-risk populations.Communications medicine · 2026Review
- Hereditary Pancreatic Cancer: Genetic Risk, Surveillance Strategies, and Therapeutic Implications.International journal of molecular sciences · 2026Review
- Barriers and facilitators of adherence to cancer prevention in Lynch Syndrome: an integrative review.Hereditary cancer in clinical practice · 2026Review
- Colorectal Cancer Screening in Hereditary and Familial High-Risk Populations: Best Practices and Future Directions.International journal of cancer · 2026Review
- Transitioning from the Prospective Lynch Syndrome Database (PLSD) to the International Lynch Syndrome Database (ILSD).Familial cancer · 2026Article
- The impact of international care networks on the clinical management of constitutional mismatch repair deficiency (CMMRD): a review of recent developments.Familial cancer · 2026Review
- Factors Associated with Adherence to Recommended Colorectal Surveillance Intervals in Lynch Syndrome.Cancers · 2026Article
269 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issuedCorrection:2020
Authors and funding
40 authors at 20 institutions in 12 countries.
Pål MøllerDepartment of Medical Genetics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Toni T SeppäläDepartment of Gastrointestinal Surgery, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
Inge BernsteinThe Danish Hereditary Non-polyposis Colorectal Cancer Register, Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark.
Elke Holinski-FederMedizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Ziemssenstr, Germany.
Paulo SalaUnit of Hereditary Digestive Tract Tumors IRCCS Istituto Nazionale Tumori Milan, Milano, Italy.
D Gareth EvansManchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, London, UK.
Annika LindblomDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Finlay MacraeColorectal Medicine and Genetics, The Royal Melbourne Hospital, Melborne, Australia.
Ignacio BlancoHereditary Cancer Program, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Rolf H SijmonsDepartment of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Jacqueline JeffriesDivision of Cancer and Genetics, Institute of Medical Genetics, Cardiff University School of Medicine, Heath Park, UK.
Hans F A VasenDepartment of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands.
John BurnInstitute of Genetic Medicine Newcastle University, Newcastle upon Tyne, UK.
Sigve NakkenDepartment of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, part of Oslo University Hospital, Olso, Norway.
Eivind HovigDepartment of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, part of Oslo University Hospital, Olso, Norway.
Einar Andreas RødlandDepartment of Tumor Biology, Institute of Cancer Research, The Norwegian Radium Hospital, part of Oslo University Hospital, Olso, Norway.
Kukatharmini TharmaratnamDepartment of Mathematics and Statistics, Lancaster University, Lancaster, UK.
Wouter H de Vos Tot Nederveen CappelDepartment of Gastroenterology and Hepatology, Isala Clinics, Zwolle, The Netherlands.
James HillDepartment of Surgery, Central Manchester University Hospitals NHS Foundation Trust and University of Manchester, London, UK.
Juul T WijnenDepartment of Clinical Genetics and Department of Human Genetics Leiden, University Medical Centre, Leiden, The Netherlands.
Mark A JenkinsCentre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia.
Kate GreenManchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, London, UK.
Fiona LallooManchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, London, UK.
Lone SundeDepartment of Surgical Gastroenterology, Aalborg University Hospital, Aalborg, Denmark.
Miriam MintsDepartment of Women's and Children's health, Division of Obstetrics and Gyneacology, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, Sweden.
Lucio BertarioUnit of Hereditary Digestive Tract Tumors IRCCS Istituto Nazionale Tumori Milan, Milano, Italy.
Marta PinedaHereditary Cancer Program, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Matilde NavarroHereditary Cancer Program, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Monika MorakMedizinische Klinik und Poliklinik IV, Campus Innenstadt, Klinikum der Universität München, Ziemssenstr, Germany.
Laura Renkonen-SinisaloDepartment of Gastrointestinal Surgery, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland.
Mev Dominguez ValentinDepartment of Medical Genetics, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Ian M Frayling
John-Paul PlazzerColorectal Medicine and Genetics, The Royal Melbourne Hospital, Melborne, Australia.
Kirsi PylvanainenDepartment of Education and Science, Central Finland Health Care District, yväskylä, Finland.
Maurizio GenuardiInstitute of Genomic Medicine, "A. Gemelli" Faculty of Medicine, Catholic University of the Sacred Heart, Rome, Italy.
Jukka-Pekka MecklinUniversity of Eastern Finland, Kuopio, Finland.
Gabriela Moeslein
Julian R SampsonDivision of Cancer and Genetics, Institute of Medical Genetics, Cardiff University School of Medicine, Heath Park, UK.
Gabriel CapellaHereditary Cancer Program, Institut Català d'Oncologia-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Mallorca Group
Oslo University Hospital · NOInstitut d'Investigació Biomédica de Bellvitge · ESLeiden University · NLUniversity of Manchester · GBCancer Genetics (United States) · USFondazione IRCCS Istituto Nazionale dei Tumori · ITLMU Klinikum · DEThe Royal Melbourne Hospital · AUUniversity of Helsinki · FIAalborg University Hospital · DKAarhus University · DKCentral Finland Health Care District · FIIsala · NLKarolinska Institutet · SEKarolinska University Hospital · SELancaster University · GBNewcastle University · GBThe University of Melbourne · AUUniversity Medical Center Groningen · NLUniversity of Eastern Finland · FI
Funding
Wellcome Trust
Abstract
backgroundMost patients with OBJECTIVE AND
designThis observational, international, multicentre study aimed to determine prospectively observed incidences of cancers and survival in
results3119 patients were followed for a total of 24 475 years. Cumulative incidences at 75 years (risks) for colorectal cancer were 46%, 43% and 15% in path_
conclusionCarriers of different
Indexed as
AgedAge FactorsColonic NeoplasmsColorectal Neoplasms, Hereditary NonpolyposisDatabases, FactualFemaleHumansIncidenceMalePancreatic NeoplasmsProspective StudiesUrogenital Neoplasmscancer preventionclinical trialscolorectal cancer screeningHNPCC syndromeinherited cancers
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.